All In Biotech

Drug Trial Radar · NCT05443126

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0031 in Patients With Advanced RET-altered Malignancies

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

265

Planned (sponsor's estimate)

Start

Sep 30, 2022

Primary completion

Mar 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Ellipses PharmaIndustry
Sponsor type
Industry
First posted
Jul 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.

Conditions

  • NSCLC

Interventions

  • EP0031Drug

    EP0031 is a potent next-generation selective RET-inhibitor (SRI)

  • Platinum chemotherapyDrug

    One of either Cisplatin or Carboplatin. Both agents are potent platinum-based antineoplastic/alkylating agents administered as an IV infusion according to local practice and labels.

  • PemetrexedDrug

    Pemetrexed is a chemotherapy medication and antifolate metabolic inhibitor administered as an IV infusion according to local practice and labels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Module B: Incidence of Dose-limiting Toxicity (DLTs ) during the first 21 days of EP0031 given in combination with SOC chemotherapy treatmentTime frame: First 21 days of treatment

Locations

52 sites in 8 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California · Recruiting

  • Stanford University

    Stanford, California · Recruiting

  • Georgetown University

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialist

    Fort Myers, Florida · Terminated

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Florida Cancer Specialists & Research Institute

    West Palm Beach, Florida · Recruiting

  • RUSH University Medical Center

    Chicago, Illinois · Terminated

  • Northwestern University

    Evanston, Illinois · Recruiting

  • University of Kentucky

    Lexington, Kentucky · Terminated

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Karmanos

    Detroit, Michigan · Terminated

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • The Ohio State University - Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Providence Portland Medical Centre

    Portland, Oregon · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Withdrawn

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Terminated

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • Washington University - School of Medicine

    Seattle, Washington · Recruiting

  • University of Washington - Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Institut Bergonié

    Bordeaux, France · Recruiting

  • Centre François Baclesse

    Caen, France · Recruiting

  • Centre Léon Bérard

    Lyon, France · Recruiting

  • Assistance Publique - Hôpitaux de Marseille

    Marseille, France · Recruiting

  • Institut Gustave Roussy

    Paris, France · Recruiting

  • Charité Comprehensive Cancer Center

    Berlin, Germany · Recruiting

  • Universitätsklinikum Köln

    Cologne, Germany · Recruiting

  • Ludwig-Maximilians-Universität München (LMU)

    München, Germany · Not yet recruiting

  • Centro di Riferimento Oncologico IRCCS

    Aviano, Italy · Recruiting

  • IRCCSS AOU Bologna

    Bologna, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Not yet recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Istituto Nazionale Tumori Regina Elena

    Roma, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga

    Torino, Italy · Recruiting

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie

    Warsaw, Poland · Not yet recruiting

  • Hospital Universitario de A Coruña

    A Coruña, Spain · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Insular de Gran Canaria

    Las Palmas de Gran Canaria, Spain · Recruiting

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.